Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Zolgensma
Zolgensma
Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA
Xtalks
Tue, 06/8/21 - 12:19 pm
Novartis
Zolgensma
SMA
gene therapy
Zolgensma flatlines, but Spinraza isn’t the beneficiary
EP Vantage
Wed, 04/28/21 - 10:27 am
SMA
Biogen
Novartis
Roche
Spinraza
Zolgensma
Evrysdi
Former AveXis executives launch gene therapy startup with uncommon targets
BioPharma Dive
Thu, 02/25/21 - 09:34 am
biotech
startups
AveXis
Zolgensma
gene therapy
Jaguar Gene Therapy
Novartis' Q4 earnings clouded by regulatory setbacks on inclisiran, Zolgensma
Endpoints
Tue, 01/26/21 - 11:30 am
Novartis
earnings
inclisiran
Zolgensma
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
BioPharma Dive
Mon, 10/5/20 - 11:39 pm
SMA
spinal muscular atrophy
Novartis
Zolgensma
Spinraza
Roche
Evrysdi
FDA sets back Novartis plans to expand use of SMA gene therapy
BioPharma Dive
Wed, 09/23/20 - 10:39 am
Novartis
SMA
gene therapy
Zolgensma
clinical trials
FDA
Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients
MedCity News
Tue, 07/21/20 - 10:37 am
Biogen
clinical trials
Spinraza
Novartis
Zolgensma
SMA
spinal muscular atrophy
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy
Fierce Pharma
Wed, 05/20/20 - 10:50 am
Novartis
Zolgensma
SMA
spinal muscular atrophy
gene therapy
Europe
Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst
Fierce Pharma
Wed, 04/8/20 - 11:03 am
Roche
FDA
risdiplam
Biogen
Spinraza
Novartis
Zolgensma
SMA
No sanctions for Novartis as FDA ends review of gene therapy violations
BioSpace
Tue, 03/31/20 - 11:14 am
Novartis
AveXis
Zolgensma
data manipulation
A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy
Xconomy
Tue, 03/31/20 - 10:49 am
SMA
Novartis
gene therapy
Zolgensma
Novartis publishes long-term data from SMA gene therapy
Pharmaforum
Tue, 03/24/20 - 10:31 am
Novartis
Zolgensma
gene therapy
SMA
With supply tight, Novartis readies gene therapy plant for production
BioPharma Dive
Fri, 02/21/20 - 11:45 pm
Novartis
Zolgensma
spinal muscular atrophy
drug manufacturing
Novartis faces criticism over Zolgensma ‘health lottery’
PM Live
Thu, 02/6/20 - 11:51 pm
Novartis
SMA
gene therapy
Zolgensma
lottery
Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter
Stat
Wed, 01/29/20 - 10:37 am
Novartis
Zolgensma
SMA
Novartis' David Lennon on next steps for AveXis, selling Zolgensma's price to the public
BioPharma Dive
Wed, 01/15/20 - 11:36 pm
Novartis
SMA
AveXis
Zolgensma
drug pricing
Four Major Biopharma Scandals in 2019
BioSpace
Thu, 01/2/20 - 10:44 am
scandal
Novartis
Zolgensma
data manipulation
China
CRISPR
IP theft
Purdue Pharma
Sackler family
oxycontin
Zolgensma for free? Yes, but advocates worry about Novartis' lottery-style giveaway
Fierce Pharma
Thu, 12/19/19 - 12:57 pm
Novartis
Zolgensma
SMA
gene therapy
drug pricing
patients
Drug Launch of the Year: Zolgensma
Biopharma Dive
Mon, 12/9/19 - 09:50 am
drug launches
Novartis
Zolgensma
SMA
Novartis says delayed telling FDA of Zolgensma concern due to "mistake"
Yahoo/Reuters
Sat, 11/2/19 - 07:51 pm
Novartis
FDA
Zolgensma
SMA
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »